Cabozantinib-associated therapy-refractory lower-leg ulcers in metastatic renal cell carcinoma

Zhide Meng, Tobias M Franz, Benedikt Hindelang, Susanne A Steimle-Grauer, Tilo Biedermann · 2026

Read Cabozantinib-associated therapy-refractory lower-leg ulcers in metastatic renal cell carcinoma by Zhide Meng, Tobias M Franz, Benedikt Hindelang, Susanne A Steimle-Grauer, Tilo Biedermann (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13527509.txt.

Description

Meng and colleagues reported a 2026 case of stubborn lower-leg ulcers linked to cabozantinib, in a man with kidney cancer that had spread widely. Cabozantinib is a targeted cancer drug that blocks blood vessel growth signals. His cancer had first been treated with immunotherapy, stopped for a severe skin reaction, and he switched to cabozantinib in 2022 after radiation failed, with a good tumor response.

Meng describes how a small spontaneous ulcer appeared on his right leg about six months into cabozantinib treatment, on a background of untreated poor vein circulation. It worsened into a painful, treatment-resistant wound by mid-2024. The drug was paused on suspicion of toxicity, swabs found only normal skin bacteria. A biopsy showed an inflammation pattern resembling pyoderma gangrenosum, an ulcer disease driven by immune cells. The authors discuss how vessel-blocking drugs impair wound healing and outline management lessons for similar patients.

Catalog record

CREATORZhide Meng, Tobias M Franz, Benedikt Hindelang, Susanne A Steimle-Grauer, Tilo Biedermann
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE10 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13527509

Browse the full library · About the Tower of Babel